Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment
Location: Sweden, Stockholm
Employees: 11-50
Investors 1
| Date | Name | Website |
| - | Flerie Inv... | flerie.com |
Mentions in press and media 3
| Date | Title | Description |
| 05.06.2025 | TIRmed Pharma appoints Peder Walberg to the board – strengthens position ahead of clinical phase | TIRmed Pharma appoints Peder Walberg to the board – strengthens position ahead of clinical phase Thu, Jun 05, 2025 07:00 CET Report this content Sciety’s portfolio company TIRmed Pharma has strengthened its board with the appointment of Ped... |
| 31.03.2023 | What M&A slowdown? Buyers circle GreenLight Biosciences, Egetis Therapeutics | While biotech M&A may have cooled down over the past year, no one has told GreenLight Biosciences or Egetis Therapeutics, which are both mulling takeover offers. RNA-focused GreenLight announced yesterday that it has received an offer f... |
| 04.11.2021 | Interim ReportQ32021 | Interim report January-September 2021 Emcitate® receives FDA Fast Track Designation Financial overview July - September Quarterly net revenue MSEK 6.2 (2.6) Quarterly loss MSEK -22.5(-24.7) Cash and cash equivalents MSEK 173.2 (159.4) Cash ... |